Page Title

Tuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed newborns as study shows

A clinical trial in South Africa has now shown that the new vaccine candidate VPM1002, developed by Max Planck researcher Stefan H.E. Kaufmann and his team, is equally safe for newborns with and without HIV exposure and has fewer side effects compared to BCG. Please click here to read the publication or visit the website.